Related Experiment Video

Updated: Jun 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Therapeutic options to further lower C-reactive protein for patients on statin treatment

Parag H Joshi1, Terry A Jacobson

  • 1Department of Medicine, Emory University, 69 Jesse Hill Jr Drive, Atlanta, GA 30303, USA. Parag.joshi@piedmont.org

Current Atherosclerosis Reports
|April 29, 2010
PubMed

Insights

This review examines high-sensitivity C-reactive protein (hsCRP) in statin trials. While some statin combinations affect hsCRP, evidence for improved cardiovascular risk reduction beyond statin monotherapy is currently lacking.

Area of Science:

  • Cardiology
  • Inflammation Biology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a primary cause of death globally.
  • Inflammation is recognized as a key factor in CVD development.
  • High-sensitivity C-reactive protein (hsCRP) is a biomarker linked to cardiovascular risk.

Purpose of the Study:

  • To review hsCRP changes in major statin outcome trials.
  • To explore the concept of targeting both low-density lipoprotein cholesterol (LDL-C) and hsCRP.
  • To assess the impact of statin combination therapies on hsCRP levels.

Main Methods:

  • Review of results from major statin outcome trials focusing on hsCRP.
  • Analysis of studies evaluating combination therapies (statin + ezetimibe, fenofibric acid, niacin, colesevelam) and their effect on hsCRP.
  • Examination of existing evidence regarding cardiovascular risk reduction with combination therapies.

Main Results:

  • Statin trials show a correlation between hsCRP levels and cardiovascular risk.
  • Some statin combination therapies demonstrate additional effects on hsCRP and other lipids.
  • Current evidence does not conclusively support cardiovascular risk reduction benefits of combination therapies over statin monotherapy.

Conclusions:

  • Further placebo-controlled trials are needed to clarify the role of targeting hsCRP versus LDL-C for cardiovascular risk reduction.
  • Current evidence suggests prioritizing low-density lipoprotein cholesterol (LDL-C) targets in managing cardiovascular risk.
  • The clinical significance of hsCRP reduction beyond LDL-C lowering by combination therapies remains to be established.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...